ADAM8 | ADAM metallopeptidase domain 8 | CD markers Enzymes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AIF1L | Allograft inflammatory factor 1-like | | | | | | Tissue enhanced |
ALOX5 | Arachidonate 5-lipoxygenase | Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
APOBEC3A | Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A | | | | | | Tissue enhanced |
ARG1 | Arginase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
BANK1 | B-cell scaffold protein with ankyrin repeats 1 | Disease related genes
| | | | | Tissue enhanced |
BTK | Bruton agammaglobulinemia tyrosine kinase | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
C17orf53 | Chromosome 17 open reading frame 53 | | | | | | Tissue enhanced |
C5AR2 | Complement component 5a receptor 2 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CARD11 | Caspase recruitment domain family, member 11 | Cancer-related genes Disease related genes
| | | | | Tissue enhanced |
CCL21 | Chemokine (C-C motif) ligand 21 | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CCNE1 | Cyclin E1 | Cancer-related genes
| | | | | Tissue enhanced |
CD180 | CD180 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD2 | CD2 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD22 | CD22 molecule | CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD226 | CD226 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD247 | CD247 molecule | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CD27 | CD27 molecule | Cancer-related genes CD markers Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CD300LF | CD300 molecule-like family member f | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD3D | CD3d molecule, delta (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD3E | CD3e molecule, epsilon (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CD3G | CD3g molecule, gamma (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD40LG | CD40 ligand | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
CD48 | CD48 molecule | CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD5 | CD5 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD6 | CD6 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD69 | CD69 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD7 | CD7 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD79A | CD79a molecule, immunoglobulin-associated alpha | Cancer-related genes CD markers Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD79B | CD79b molecule, immunoglobulin-associated beta | Cancer-related genes CD markers Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
CD80 | CD80 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD83 | CD83 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD8A | CD8a molecule | CD markers Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD8B | CD8b molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CDA | Cytidine deaminase | Enzymes Plasma proteins
| | | | | Tissue enhanced |
CDCA4 | Cell division cycle associated 4 | | | | | | Tissue enhanced |
CDCA5 | Cell division cycle associated 5 | | | | | | Tissue enhanced |
CDH4 | Cadherin 4, type 1, R-cadherin (retinal) | Predicted membrane proteins
| | | | | Tissue enhanced |
CENPF | Centromere protein F, 350/400kDa | Cancer-related genes Plasma proteins
| | | | | Tissue enhanced |
CENPU | Centromere protein U | | | | | | Tissue enhanced |
CKAP2L | Cytoskeleton associated protein 2-like | | | | | | Tissue enhanced |
CLC | Charcot-Leyden crystal galectin | | | | | | Tissue enhanced |
CLEC12A | C-type lectin domain family 12, member A | Predicted membrane proteins
| | | | | Tissue enhanced |
CLEC4A | C-type lectin domain family 4, member A | Predicted membrane proteins
| | | | | Tissue enhanced |
CR1 | Complement component (3b/4b) receptor 1 (Knops blood group) | Blood group antigen proteins CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CTD-2207O23.3 | Rho guanine nucleotide exchange factor 18 | | | | | | Tissue enhanced |
CTSW | Cathepsin W | Enzymes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CXCL5 | Chemokine (C-X-C motif) ligand 5 | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CXCR2 | Chemokine (C-X-C motif) receptor 2 | Cancer-related genes CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CXCR3 | Chemokine (C-X-C motif) receptor 3 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |